about
Guidelines for the use and interpretation of assays for monitoring autophagyFunctional activities and cellular localization of the ezrin, radixin, moesin (ERM) and RING zinc finger domains in MIRFibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap)Mylip makes an Idol turn into regulation of LDL receptorIdentification and characterisation of transcript and protein of a new short N-terminal utrophin isoformPDGF regulates the actin cytoskeleton through hnRNP-K-mediated activation of the ubiquitin E3-ligase MIRInduction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheresCell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsImage-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support.Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.Clinical or ATPase domain mutations in ABCD4 disrupt the interaction between the vitamin B12-trafficking proteins ABCD4 and LMBD1.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.Dexamethasone regulates expression of BRUCE/Apollon and the proliferation of neural progenitor cells.Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse.CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Leukemia surfaceome analysis reveals new disease-associated features.Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic LeukemiaPre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphomaUSP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell LeukemiaShort communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice)Alternative technique for intrafemoral injection and bone marrow sampling in mouse transplant modelsEfficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7
P50
Q21996341-09293719-8549-40DC-A06B-5D231FAA5856Q24297509-F9975E35-04BC-43D6-AD9B-D9D1FF257061Q24306597-81AB20BF-713B-4C64-B077-D3A942B81D91Q28255464-2E3932A2-4FD5-4D55-8155-DD6B7665DC56Q28580577-ECE2A1B2-30C6-4A15-80F4-40B8CAFF8BE5Q30477228-DFDBF0A5-F961-4F9A-85B4-C3E184425B07Q33755338-3363A0A6-F58B-4EC9-8E16-91E58F40CA68Q33908271-EB249115-10F0-431F-BA8C-C15360333C1BQ34135333-2F788E43-5ACC-4DB6-9126-99A61DD74236Q34957024-EAE40C2D-7EF6-48E6-8AEA-ADFB2234D6D4Q36154689-B33D2F46-4F26-4647-BFEE-ADFCE77FC4BFQ36340868-4AAF1133-C127-4946-B5DA-74D969EEAF7AQ38701568-190E42BC-94CB-472A-AEE4-2FC371C98F39Q38722012-690BAA87-D852-4E6A-827A-1BDE7FF2AFC4Q38999126-34451BFB-F0C4-4BF2-826C-27D374FF44E6Q40204818-49CF5171-165D-40E8-A356-278897B3FB13Q41791770-4CDFDAE1-E2FE-436B-A175-C4FCA0BE8DB9Q42264347-B2FBD10E-E735-4219-94E2-3C200E646997Q42807400-AB24AB4F-A9E3-40B8-8B69-EBFDE2A52625Q42923393-B8160405-2A40-4F0E-A7F8-9F5D25B0896CQ45891227-9D79B181-5023-4D48-93C7-BF89AA13608BQ50300618-CC8A836C-ABE8-4188-935F-9A7955F81311Q50477441-B14AE720-B878-40FF-B661-FE7A3784CAF3Q50868234-4141C782-AAA4-4F90-845F-32F79EAA644AQ51015448-EDE8DB8E-DC5E-462B-A500-4E41D58968EDQ58785945-2109DCCD-41A5-42BA-B0F0-D53EEB388458Q60922639-2D11090F-4268-49AA-9ADE-2640CB72513AQ61816131-3D8C3497-7057-4959-837E-7E761F465312Q73265192-767FC8BF-1EBE-4999-BB2C-1AB19980D657Q84333868-B4833706-901C-4F18-89F4-1450387687F3Q92488293-F0162873-262C-461A-91A1-79AFF2ED8AFF
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-2890-3191
@en
name
Beat C Bornhauser
@ast
Beat C Bornhauser
@en
Beat C Bornhauser
@nl
type
label
Beat C Bornhauser
@ast
Beat C Bornhauser
@en
Beat C Bornhauser
@nl
altLabel
Beat Bornhauser
@en
prefLabel
Beat C Bornhauser
@ast
Beat C Bornhauser
@en
Beat C Bornhauser
@nl
P106
P31
P496
0000-0003-2890-3191